6-(2-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-methyl-1H-indol-5-yl)-5-ethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid | 1426525-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 6-(2-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-methyl-1H-indol-5-yl)-5-ethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
• 英文别名: 6-[2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1-methylindol-5-yl]-5-ethyl-2-oxo-1H-pyridine-3-carboxylic acid
• CAS: 1426525-06-5
• 化学式: C₂₇H₂₇N₃O₃
• 分子量: 441.53
• InChiKey: ALIMRMUTCSJGRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS MÉTHODES D'UTILISATION
  申请人：PTC THERAPEUTICS INC

  公开号：WO2013033258A1

  公开（公告）日：2013-03-07

  The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

  本文描述了化合物、形式及其制药组合物以及使用方法，用于治疗或缓解由野生型和多重耐药革兰氏阴性和革兰氏阳性病原体引起的细菌感染。
• ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE
  申请人：PTC THERAPEUTICS, INC.

  公开号：US20150038437A1

  公开（公告）日：2015-02-05

  The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

  本说明涉及化合物和形式以及其制药组合物，以及使用它们治疗或改善由野生型和多重耐药革兰氏阴性和革兰氏阳性病原体引起的细菌感染的方法。
• US9409905B2
  申请人：——

  公开号：US9409905B2

  公开（公告）日：2016-08-09
• [EN] BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE BRODOMAINES CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2013033270A2

  公开（公告）日：2013-03-07

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
• [EN] BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS 2-PYRIDINONE SUBSTITUÉS BICYCLIQUES ET TRICYCLIQUES ANTIBACTÉRIENS
  申请人：PTC THERAPEUTICS INC

  公开号：WO2016039937A1

  公开（公告）日：2016-03-17

  The present description relates to the use of bicyclic and tricyclic ring substituted 2-pyridinone compounds and forms thereof for treating or ameliorating Neisseria gonorrhoeae. The present description relates to use of a substituted 2-pyridinone compound for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae) in a subject in need thereof comprising, administering an effective amount of a compound of Formula (I) or a form thereof to the subject: wherein R1, R2 and R3 are as defined herein, and forms and compositions thereof.